{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T05:05:21Z","timestamp":1789103121802,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007950","name":"Tanta University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007950","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Healive is an inactivated vaccine for hepatitis A virus developed in China and was found to be well-tolerated and highly immunogenic in adults and children. It is our aim this study to compare the safety and immunogenicity of Healive\u00ae with Havrix\u00ae and live attenuated vaccines in pediatric populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of PubMed, Scopus, Web of Science, and Embase databases was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) comparing Healive with other vaccines were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seven RCTs involving 3664 patients were included. Healive showed comparable efficacy to Havrix regarding seroconversion rates and GMT at one month (SMD\u2009=\u20090.24, 95% CI [-0.11 to 0.59]), but achieved better results at six (SMD\u2009=\u20090.85, 95% CI [0.57 to 1.07]) and seven months (SMD\u2009=\u20090.55, 95% CI [0.41 to 0.70]). When compared to live attenuated vaccines, Healive demonstrated superior GMT at one month (SMD\u2009=\u20090.31, 95% CI [0.07 to 0.56]) and two years (SMD\u2009=\u20090.36, 95% CI [0.06 to 0.67]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Healive appears to be effective and safe for preventing hepatitis A, providing at least five years of protection. This review underscores the importance of ongoing research to optimize hepatitis A vaccination strategies, including standardized assays for antigen content, clarification of protective antibody levels, and large-scale trials in regions of intermediate endemicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13052-025-01996-8","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T04:06:17Z","timestamp":1764648377000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of safety and immunogenicity between Healive\u00ae, Havrix\u00ae and live attenuated Hepatitis A vaccines in pediatric population: a systematic review with meta-analysis"],"prefix":"10.1186","volume":"51","author":[{"given":"Mohamed","family":"Abo Zeid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Elrosasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3277-2270","authenticated-orcid":false,"given":"Mohamad Ali","family":"Farho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9457-9832","authenticated-orcid":false,"given":"Mohamed","family":"Rifai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7648-2224","authenticated-orcid":false,"given":"Menna M.","family":"Aboelkhier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Nabil","family":"Elkhrashy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Hamdy","family":"Zabady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Samir A.","family":"Zaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman Mostafa","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy A.","family":"Dawood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2894-7875","authenticated-orcid":false,"given":"Yasmine","family":"Abuzaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"1996_CR1","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1080\/21645515.2020.1819742","volume":"17","author":"C Herzog","year":"2021","unstructured":"Herzog C, Van Herck K, Van Damme P. Hepatitis A vaccination and its immunological and epidemiological long-term effects \u2013 a review of the evidence. Hum Vaccin Immunother. 2021;17:1496\u2013519.","journal-title":"Hum Vaccin Immunother"},{"key":"1996_CR2","unstructured":"World Health Organization. (2012). WHO position paper on hepatitis A vaccines \u2013 June 2012. Weekly Epidemiological Record, 87(26), 261\u2013276."},{"key":"1996_CR3","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1016\/j.vaccine.2007.11.008","volume":"26","author":"W-P Jiang","year":"2008","unstructured":"Jiang W-P, et al. Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive\u00ae): A double-blind, randomized and controlled trial. Vaccine. 2008;26:2297\u2013301.","journal-title":"Vaccine"},{"key":"1996_CR4","first-page":"35","volume":"22","author":"Y Poovorawan","year":"1991","unstructured":"Poovorawan Y, Paiboonkasemsuthi S, Theamboonlers A, Kamolratanakul P, Chumdermpadetsuk S. Seroepidemiology of antibody to hepatitis A in the rural eastern part of Thailand. Southeast Asian J Trop Med Public Health. 1991;22:35\u20138.","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"1996_CR5","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/jvh.12564","volume":"23","author":"C-M Chen","year":"2016","unstructured":"Chen C-M, Chen SC-C, Yang H-Y, Yang S-T, Wang C-M. Hospitalization and mortality due to hepatitis A in Taiwan: a 15-year nationwide cohort study. J Viral Hepat. 2016;23:940\u20135.","journal-title":"J Viral Hepat"},{"key":"1996_CR6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1542\/peds.109.5.839","volume":"109","author":"GL Armstrong","year":"2002","unstructured":"Armstrong GL, Bell BP. Hepatitis a virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics. 2002;109:839\u201345.","journal-title":"Pediatrics"},{"key":"1996_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.7326\/0003-4819-128-2-199801150-00006","volume":"128","author":"IR Willner","year":"1998","unstructured":"Willner IR. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med. 1998;128:111.","journal-title":"Ann Intern Med"},{"issue":"Suppl 1","key":"1996_CR8","doi-asserted-by":"publisher","first-page":"S160","DOI":"10.1016\/0264-410X(92)90576-6","volume":"10","author":"FE Andr\u00e9","year":"1992","unstructured":"Andr\u00e9 FE, D\u2019Hondt E, Delem A, Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine. 1992;10(Suppl 1):S160\u20138.","journal-title":"Vaccine"},{"key":"1996_CR9","first-page":"72","volume":"37","author":"FE Andr\u00e9","year":"1990","unstructured":"Andr\u00e9 FE, Hepburn A, D\u2019Hondt E. Inactivated candidate vaccines for hepatitis A. Prog Med Virol. 1990;37:72\u201395.","journal-title":"Prog Med Virol"},{"key":"1996_CR10","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1093\/infdis\/171.Supplement_1.S44","volume":"171","author":"R Clemens","year":"1995","unstructured":"Clemens R, et al. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis. 1995;171:S44\u20139.","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"1996_CR11","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1016\/S0264-410X(99)00467-3","volume":"18","author":"BN Barzaga","year":"2000","unstructured":"Barzaga BN. Hepatitis A shifting epidemiology in South-East Asia and China. Vaccine. 2000;18(Suppl 1):S61\u20134.","journal-title":"Vaccine"},{"key":"1996_CR12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.4161\/21645515.2014.979646","volume":"11","author":"M Mitra","year":"2015","unstructured":"Mitra M, et al. Long term follow-up study to evaluate immunogenicity and safety of a single dose of live attenuated hepatitis a vaccine in children. Hum Vaccin Immunother. 2015;11:1147\u201352.","journal-title":"Hum Vaccin Immunother"},{"key":"1996_CR13","doi-asserted-by":"publisher","unstructured":"Mitra M. et al. Changing epidemiology of hepatitis A virus in Indian children. Vaccine: Development and Therapy. 2014;7. https:\/\/doi.org\/10.2147\/VDT.S53324.","DOI":"10.2147\/VDT.S53324"},{"key":"1996_CR14","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1080\/21645515.2016.1216286","volume":"12","author":"S Rao","year":"2016","unstructured":"Rao S, Mao JS, Motlekar S, Fangcheng Z, Kadhe G. A review of immunogenicity and tolerability of live attenuated Hepatitis A vaccine in children. Hum Vaccin Immunother. 2016;12:3160\u20135.","journal-title":"Hum Vaccin Immunother"},{"key":"1996_CR15","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S0264-410X(96)00304-0","volume":"15","author":"JS Mao","year":"1997","unstructured":"Mao JS, et al. Further evaluation of the safety and protective efficacy of live attenuated hepatitis A vaccine (H2-strain) in humans. Vaccine. 1997;15:944\u20137.","journal-title":"Vaccine"},{"key":"1996_CR16","first-page":"188","volume":"22","author":"F Zhuang","year":"2001","unstructured":"Zhuang F, Jiang Q, Gong Y. Epidemiological effects of live attenuated hepatitis A vaccine (H(2)-strain): results of A 10-year observation. Zhonghua Liu Xing Bing Xue Za Zhi. 2001;22:188\u201390.","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"1996_CR17","first-page":"1851","volume":"118","author":"F Zhuang","year":"2005","unstructured":"Zhuang F, et al. Persistent efficacy of live attenuated hepatitis A vaccine (H2-strain) after a mass vaccination program. Chin Med J (Engl). 2005;118:1851\u20136.","journal-title":"Chin Med J (Engl)"},{"key":"1996_CR18","first-page":"1013","volume":"24","author":"Y Ren","year":"2003","unstructured":"Ren Y, et al. The study on the 0, 12 month vaccination schedule\u2019 of Healive inactivated hepatitis A vaccine in children. Zhonghua Liu Xing Bing Xue Za Zhi. 2003;24:1013\u20135.","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"1996_CR19","first-page":"1483","volume":"115","author":"A Ren","year":"2002","unstructured":"Ren A, Feng F, Ma J, Xu Y, Liu C. Immunogenicity and safety of a new inactivated hepatitis A vaccine in young adults: a comparative study. Chin Med J (Engl). 2002;115:1483\u20135.","journal-title":"Chin Med J (Engl)"},{"key":"1996_CR20","doi-asserted-by":"crossref","unstructured":"Higgins JPT. et al. Cochrane handbook for systematic reviews of interventions. 2019.","DOI":"10.1002\/9781119536604"},{"key":"1996_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. 2021;134:103\u201312.","journal-title":"J Clin Epidemiol"},{"key":"1996_CR22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.","journal-title":"Syst Rev"},{"key":"1996_CR23","doi-asserted-by":"publisher","unstructured":"Sterne JAC. et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898\u2013l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"1996_CR24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12:55\u201361.","journal-title":"Res Synth Methods"},{"key":"1996_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"1996_CR26","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1080\/21645515.2016.1197450","volume":"12","author":"C Yu","year":"2016","unstructured":"Yu C, et al. Comparison of immunogenicity and persistence between inactivated hepatitis A vaccine Healive\u00ae and Havrix\u00ae among children: a 5-year follow-up study. Hum Vaccin Immunother. 2016;12:2595\u2013602.","journal-title":"Hum Vaccin Immunother"},{"key":"1996_CR27","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.4161\/hv.24366","volume":"9","author":"X Liu","year":"2013","unstructured":"Liu X, et al. Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines. Hum Vaccin Immunother. 2013;9:1460\u20135.","journal-title":"Hum Vaccin Immunother"},{"key":"1996_CR28","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/infdis\/jiv213","volume":"212","author":"X Liu","year":"2015","unstructured":"Liu X, et al. Comparison of immunogenicity between inactivated and live attenuated hepatitis a vaccines among young adults: a 3-year follow-up study. J Infect Dis. 2015;212:1232\u20136.","journal-title":"J Infect Dis"},{"key":"1996_CR29","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1016\/j.vaccine.2012.04.038","volume":"30","author":"Z-L Zhang","year":"2012","unstructured":"Zhang Z-L, et al. Interchangeability and tolerability of two inactivated hepatitis A vaccines in Chinese children. Vaccine. 2012;30:4028\u201333.","journal-title":"Vaccine"},{"key":"1996_CR30","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1080\/21645515.2016.1278329","volume":"13","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, et al. Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine. Hum Vaccin Immunother. 2017;13:1314\u20139.","journal-title":"Hum Vaccin Immunother"},{"key":"1996_CR31","doi-asserted-by":"publisher","first-page":"9098","DOI":"10.1016\/j.vaccine.2011.08.078","volume":"29","author":"H Zheng","year":"2011","unstructured":"Zheng H, et al. Comparing live attenuated and inactivated hepatitis A vaccines: An immunogenicity study after one single dose. Vaccine. 2011;29:9098\u2013103.","journal-title":"Vaccine"},{"key":"1996_CR32","doi-asserted-by":"publisher","first-page":"7166","DOI":"10.1016\/j.vaccine.2021.10.018","volume":"39","author":"S Thuluva","year":"2021","unstructured":"Thuluva S, Matur R, Tsa K, Gv SR. A single blind randomized phase 3 study to evaluate safety and immunogenicity of inactivated hepatitis A vaccine (HAPIBEVTM) in 1\u201315 years-old healthy hepatitis A vaccine-na\u00efve children. Vaccine. 2021;39:7166\u201374.","journal-title":"Vaccine"},{"key":"1996_CR33","doi-asserted-by":"publisher","unstructured":"Irving GJ, Holden J, Yang R, Pope D. Hepatitis A immunisation in persons not previously exposed to hepatitis A. Cochrane Database Syst Rev. 2012. https:\/\/doi.org\/10.1002\/14651858.CD009051.pub2.","DOI":"10.1002\/14651858.CD009051.pub2"},{"key":"1996_CR34","doi-asserted-by":"publisher","first-page":"e939","DOI":"10.1016\/j.ijid.2013.04.012","volume":"17","author":"JJ Ott","year":"2013","unstructured":"Ott JJ, Wiersma ST. Single-dose administration of inactivated hepatitis A vaccination in the context of hepatitis A vaccine recommendations. Int J Infect Dis. 2013;17:e939\u201344.","journal-title":"Int J Infect Dis"},{"key":"1996_CR35","unstructured":"Walsh N, Torres J, Curtis S. Hepatitis A childhood and adolescent vaccination: a systematic review of the effectiveness, immunogenicity, impact, safety and cost effectiveness of pediatric vaccines. 2022."},{"key":"1996_CR36","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1016\/j.vaccine.2023.02.073","volume":"41","author":"L Wu","year":"2023","unstructured":"Wu L, et al. Safety of concomitant administration of inactivated hepatitis A vaccine with other vaccines in children under 16 years old in post-marketing surveillance. Vaccine. 2023;41:2412\u20137.","journal-title":"Vaccine"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-025-01996-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13052-025-01996-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-025-01996-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:43:56Z","timestamp":1765298636000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-025-01996-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1996"],"URL":"https:\/\/doi.org\/10.1186\/s13052-025-01996-8","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"assertion":[{"value":"21 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"316"}}